This news is delayed by 15 minutes, sign up now to get live news & full features.
ALNY ALNYLAM PHARMACEUTICALS INC
+ add to watchlist
$453.37
alnylam is developing an entirely new class of innovative medicines based on a breakthrough discovery in biology known as rna interference, or rnai. with rnai technology, we have the opportunity to treat disease and impact the lives of patients in a fundamentally new way by silencing disease-causing genes upstream of today's medicines.
Mkt Cap: $58.65B
52 Week High: $469.81
P/E: -462.35
52 Week Low: $205.87
Dividend: $0.00
Shares Outstanding: 131.08M